Replimune (REPL) Liabilities and Shareholders Equity (2018 - 2026)
Replimune's Liabilities and Shareholders Equity came in at $252.45 million for fiscal Q1 2027 (quarter ended Jun 30, 2026), down 46.2% from $469.51 million a year earlier and down 24.1% from the prior quarter.
Powered by 
Analysis
Replimune (REPL) Liabilities and Shareholders Equity (2018 - 2026) Analysis & Trends
At the end of FY2026 (ended Mar 31, 2026), Replimune's Liabilities and Shareholders Equity was $332.39 million, down 39.7% from FY2025.
- Liabilities and Shareholders Equity carries a five-year compound annual growth rate of -9.4% (FY2021 to FY2026).
- Going back by fiscal year, Liabilities and Shareholders Equity was $551.33 million in FY2025 (+13.0%), $487.72 million in FY2024 (-24.6%), $646.59 million in FY2023 (+40.2%) and $461.19 million in FY2022 (-15.1%).
- The fiscal Q1 2027 figure represents the lowest quarterly Liabilities and Shareholders Equity since fiscal Q4 2020.
- Year-over-year, Liabilities and Shareholders Equity has declined for five consecutive quarters, with an average decline of 18.7% over the last eight quarters.
- The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in fiscal Q2 2022 (growth of 60.2%), and the weakest in fiscal Q1 2027 (a decline of 46.2%).
- Business Quant data shows REPL's Liabilities and Shareholders Equity at $332.39 million (Q4 2026), $333.59 million (Q3 2026) and $389.45 million (Q2 2026) in the three fiscal quarters before Q1 2027.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 142.28 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 201.06 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 135.12 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 129.80 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 122.03 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 115.83 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 95.64 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 49.36 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 201.13 Bn |
| 10 | Replimune | 1.14 Bn | 79.22 Mn | - | 252.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 252.45 Mn |
| Mar 31, 2026 | 332.39 Mn |
| Dec 31, 2025 | 333.59 Mn |
| Sep 30, 2025 | 389.45 Mn |
| Jun 30, 2025 | 469.51 Mn |
| Mar 31, 2025 | 551.33 Mn |
| Dec 31, 2024 | 603.63 Mn |
| Sep 30, 2024 | 498.20 Mn |
| Jun 30, 2024 | 534.97 Mn |
| Mar 31, 2024 | 487.72 Mn |
| Dec 31, 2023 | 532.93 Mn |
| Sep 30, 2023 | 562.40 Mn |
| Jun 30, 2023 | 603.89 Mn |
| Mar 31, 2023 | 646.59 Mn |
| Dec 31, 2022 | 678.55 Mn |
| Sep 30, 2022 | 436.10 Mn |
| Jun 30, 2022 | 459.43 Mn |
| Mar 31, 2022 | 461.19 Mn |
| Dec 31, 2021 | 485.28 Mn |
| Sep 30, 2021 | 503.46 Mn |
API Access
Replimune Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=REPL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "REPL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=REPL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();